Apotek Selected for NSF I-Corps Spark Cohort on AI/ML and Cancer Care
- Esther Chen
- Nov 11
- 2 min read
Translating AI-powered research into real-world cancer impact
Taipei | [November 12, 2025] — Vizuro is proud to announce that our Apotek platform has been selected for the National Science Foundation (NSF) I-Corps Spark Cohort, beginning November 13, 2025.
This specialized program focuses on AI/ML-powered innovations in cancer research and care, empowering teams to translate cutting-edge science into tangible impact including customer discovery and lean methodology. Participants engage directly with mentors, peers, and industry leaders to explore applications, refine value propositions, and identify commercialization pathways that address real clinical and translational challenges.
For Vizuro Apotek, this opportunity strengthens our mission to bridge AI, causal biology, and sustainable drug innovation—accelerating how causal AI and generative AI can reshape drug repositioning and discovery of cancer therapeutics.
What is NSF I-Corps
The U.S. National Science Foundation (NSF) created I-Corps to nurture and sustain a national innovation ecosystem that builds upon fundamental research to guide the output of discoveries closer to the development of technologies, products, services, and processes that benefit society.
The NSF I-Corps Hub: New England Region launched on Jan. 1, 2025. The seven institutions initially collaborating with MIT include Brown University, Harvard University, Northeastern University, Tufts University, University of Maine, University of Massachusetts Amherst, and University of New Hampshire.
🔗 More about NSF I-Corps on the NSF website↗
About Apotek
Apotek harnesses groundbreaking causal AI and generative AI technologies to build an integrated platform that transforms multi-omics data into actionable insights — enabling novel target discovery, biosimulation, and generative drug design. By uncovering cause-and-effect relationships rather than spurious correlations, our approach enhances biological interpretability, improves model robustness, and accelerates decision-making across the drug discovery pipeline.
Media Contact
Esther Chen,
Director of Business Operations of Commercialization,
Vizuro LLC